LOS ANGELES, CA, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, filed a patent infringement lawsuit today in the U.S. District Court for the Central District of California against KVP INTERNATIONAL, INC., a California Corporation, ORTHOCOR MEDICAL, INC., a Delaware Corporation, and CAERUS CORP., a Minnesota Corporation.
The lawsuit states the aforementioned companies make, market, import, use, sell, and/or offer for sale several products and related services within the United States which infringe Endonovo’s Patents.
[The lawsuit includes patent infringement against KVP International Inc. KVP makes, markets, uses, sells and offers for sale a product it refers to as its KVP Cura line, including, but not limited to the KVP Cura Patch. KVP has even trademarked the KVP Cura name it uses to refer to its infringing products and/or product line The KVP Cura line infringes, where according to KVP’s own website, “the KVP Cura line reduces pain and increases blood flow, providing effective therapy for a variety of ailments. Using PEMF technology, KVP Cura increases metabolism, blood flow, and lymphatic flow by accelerating the exchange of positive and negative ions through the cell membranes of an animal’s body.” Thus, the product line includes PEMF technology used for treating various ailments in exactly the same way as intended by the Endonovo Patents.The KVP Cura line includes a “KVP Cura Patch which attaches with Velcro for use with a wide variety of garments” according to KVP’s own website, where the Patch itself contains the PEMF technology. The Patch itself infringes certain claims of the Endonovo Patents, and can also be combined with a variety of therapeutic devices, where the combination infringes Endonovo’s patents. By instructing and/or encouraging a consumer and/or other user to combine or otherwise use a product in a particular way, KVP also indirectly infringes upon method claims within Endonovo’s Patents.]
[Endonovo is informed and believes, and on such basis alleges, KVP sought a trademark on its Cura name in October of 2017, and thus on or around this same time it also began marketing, manufacturing, utilizing, selling and offering for sale the relevant infringing products and product line.]
[Additionally, the lawsuit includes patent infringement against Orthocor Medical Inc. Orthocor is a supplier of critical components and parts to KVP, for use in KVP’s own infringing products and product line, for the ultimate sale and offers for sale of those products. Orthocor derives substantial profits, revenue and/or income from its sale of these parts and components to KVP.]
[Caerus Corp. also derives substantial profits, revenue and/or income from the sale of Orthocor’s infringing products as well as its own infringing products and product line. This includes direct sales as well as indirect sales through its own distributors and/or retailers that knowingly distribute or sell products to consumers and/or businesses.]
“All of Endonovo’s granted patents have been vigorously maintained enabling us to produce an FDA Cleared Medical Device clinically proven to significantly speed the healing process and reduce the need for pain medications” said Chief Executive Officer, Alan Collier. “Creating a product of the highest quality in the pain and wound care industry is why we are compelled to take appropriate action when necessary in the defense of our vital proprietary technology.”
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com